Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
about
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerAssociation of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cellsPhase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.Potential implications of GRP58 expression and susceptibility of cervical cancer to cisplatin and thymoquinone-based therapy.Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.Role of systemic chemotherapy in metastatic cervical cancer.Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in VivoTreatment options in recurrent cervical cancer (Review).Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer.Prospective cohort study to evaluate the efficacy of taxane plus platinum and CPT-11plus platinum regimes and to identify prognostic risk factors in cervical cancer patients.Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cellsPhase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursPrognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy.Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky massImpact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration.Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.Outcomes of a bladder preservation technique in female patients undergoing pelvic exenteration surgery for advanced gynaecological tumours.Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl
P2860
Q26799484-D9031026-82D2-462E-81D3-D53157D12958Q28271164-E6EDE657-A6C9-4DFF-8D14-9D41AEF4AEB6Q33340188-A595E98E-48A9-46F3-82F5-409F8351BA3FQ34042813-61954B7C-5199-4A02-A4EE-942A646A67AEQ34430219-9698DF7F-AE46-4D50-9AA4-01CDD864F7DEQ35117753-C23A3985-8E58-4F71-AA16-4618CD31CF2EQ35589201-86706BE0-A147-48ED-BB53-DE4DE96A0B02Q35813800-09C9463A-E1BC-4CD1-A830-2C779957ADF9Q36216582-FB9E800A-B8D3-45BB-8EA2-3A4FC6036F2CQ36216872-9E27115A-CCC8-4178-AB15-F74B8A08EE8BQ36317409-D150287F-167C-4391-818B-BE8370EC18D8Q36642323-87AF21B9-F868-4336-9A73-024F8D22224CQ36648316-DD26BA52-B573-42E9-B5B7-678DC385F60DQ36985891-1E096240-A409-4A90-9270-EE599FB00232Q37443118-B65A6368-8870-4EC1-9DED-53D02A9C651AQ40009120-E49470A0-996C-4C0D-A209-4189DF926251Q43440524-FDA7CF08-E5B5-4E56-9EEE-7B4B9C9BCD16Q44654133-78F5B8D2-7F03-466C-A364-0279389CB4EBQ51153582-41E38CC9-29A0-4419-9284-F30A3F8E4F86Q53588262-F1F6C73A-9188-4B91-97F7-3B6F71E08F78Q57017738-A61A3E6E-2537-48C3-94DC-7B9E79F82552
P2860
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@ast
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@en
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@nl
type
label
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@ast
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@en
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@nl
prefLabel
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@ast
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@en
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@nl
P2093
P356
P1433
P1476
Phase II study of irinotecan a ...... or recurrent cervical cancer.
@en
P2093
M Yakushiji
P356
10.1159/000012076
P577
2000-01-01T00:00:00Z